Smart-Money SignalNeutral · 45/100— Insiders are net sellers over 90 days (-$5K, 4 sales vs 5 buys)
Net Income-$23.3M
EPS$-2.18
Market Cap$1.6B
Price Performance
Historical data including institutional events
Company Profile
P
Paul A. Wagner
CEO & Executive Director
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
The companyâs lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo.
Forte Biosciences, Inc. is headquartered in Dallas, Texas.
